Background/Objectives: Acute myeloid leukemia (AML) remains a hematologic malignancy with poor prognosis. The neddylation inhibitor MLN4924 has demonstrated potent anti-leukemic activity in preclinical models, yet its clinical translation faces significant challenges. The aim of this study was to explore combination therapy strategies that could further enhance MLN4924’s anti-leukemia potential. Methods: AML cell lines used in this study were Kasumi-1 and MOLM-13. Cell viability was assessed using CCK-8 assays. mRNA and protein expression levels were determined through RT-qPCR and Western blot, respectively. Flow cytometry was employed to analyze surface markers (SLC1A5, CD11b, CD14, CD16), mitochondrial membrane potential (JC-1), and apoptosis (Annexin V-FITC/PI). In vivo efficacy was validated using an NCG mouse xenograft model. Transcriptomic profiling was performed to explore the potential mechanism by which MLN4924 in combination with V9302 inhibits leukemia. Results: Treatment with MLN4924 significantly upregulated key glutamine metabolic proteins, GLUL and the glutamine transporter SLC1A5, in AML cells. Knockdown of SLC1A5 significantly enhanced AML cell sensitivity to MLN4924. The combination of MLN4924 and the SLC1A5 inhibitor V9302 synergistically inhibited AML cell proliferation, induced monocytic differentiation, and promoted apoptosis. Transcriptomic analysis revealed that this combination therapy prominently suppressed the tricarboxylic acid (TCA) cycle. Conclusions: Neddylation inhibition induces compensatory upregulation of glutamine metabolism in AML. Co-targeting neddylation and glutamine transporter SLC1A5 synergistically exerts anti-leukemic effects, at least in part through disruption of the TCA cycle. This combination represents a novel and effective therapeutic strategy against AML.
Treatment response, survival outcomes, and factors related to venetoclax (VEN)-based therapy were assessed in patients with acute myeloid leukemia (AML), including newly diagnosed AML (ND-AML) and relapsed/refractory AML (R/R AML). We also developed a model to predict composite complete remission (CRc) after the first treatment cycle. This retrospective study included 216 patients with AML who received VEN-based regimens at the First Hospital of Lanzhou University between March 2020 and May 2025. Treatment response, overall survival (OS), and factors related to CRc and OS were evaluated. A multivariable model for CRc was developed and internally validated using 1,000 bootstrap resamples. Of the 216 patients, 165 had ND-AML and 51 had R/R AML. CRc was achieved in 74.5% and 39.2% of patients, respectively. In ND-AML, failure to achieve CRc, older age, and NF1 mutation were independently associated with shorter OS. In R/R AML, a lower pretreatment white blood cell count and a higher bone marrow blast percentage were associated with CRc, whereas failure to achieve CRc was associated with higher mortality. The final six-predictor model included AML status, age, bone marrow blast percentage, platelet count, Eastern Cooperative Oncology Group (ECOG) performance status, and TET2 mutation. Its apparent area under the receiver operating characteristic curve (AUC) was 0.841 (95% confidence interval, 0.785–0.897). The fixed CRc score yielded time-dependent OS AUCs of 0.788 at 6 months and 0.695 at 12 months. The model may be useful for estimating early treatment response, although external validation is needed before routine clinical application.